CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Geloen, Alain ^a   Helin, Lionel ^c   Geeraert, Benjamine ^b   Malaud, Eric ^c   Holvoet, Paul ^b   Marguerie, Gerard ^c  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Arteria ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AP 5055; AP 5156; AP 5258; CD36 ANTIGEN; CD36 INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; PROTEIN INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; FATTY ACID METABOLISM; GASTROINTESTINAL TRANSIT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; IC 50; INSULIN SENSITIVITY; LIPID STORAGE; LIPOLYSIS; MOLECULAR WEIGHT; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; RAT; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIGENS, CD36; ATHEROSCLEROSIS; BENZIMIDAZOLES; CELL LINE; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MALE; MICE; POSTPRANDIAL PERIOD; RATS; RATS, WISTAR; THIOPHENES;

RODENTIA;

EID: 84861466027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037633     Document Type: Article

References (49)

1. Endermann G, Stanton LW, Madden KS, Bryant CM, White CM, et al. (1993) CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268: 11811-11816.
2. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, et al. (2000) Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 105: 1095-1108.
3. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, et al. (2002) Scavenger receptor Class AI/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2877: 49982-49988.
4. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, et al. (2002) A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor and is enriched in atherosclerotic lesions. J Biol Chem 277: 38517-38523.
5. Febbraio M, Podrez EA, Smith DP, Hajjar DP, Hazen SL, et al. (2000) Targeted disruption of the class B receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105: 1049-1057.
6. Park YM, Febbraio M, Sylverstein RL, (2009) CD36 modulates migration of mouse and human macrophages in response to oxydized LDL and contributes to macrophage trapping in the arterial intima. J Clin Invest 119: 136-145.
7. Febbraio M, Guy E, Silverstein RL, (2004) Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler Thromb Vasc Biol 24: 2333-2338.
8. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, et al. (2005) Loss of receptor-mediated lipid uptake via scavenger receptor or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest 115: 2192-2201.
9. Harmon CM, Luce P, Abumrad NA, (1992) Labelling of an 88 kDa adipocyte membrane protein by sulpho-N-succinimidyl long chain fatty acids: inhibition fatty acid transport. Biochem Soc Trans 20: 811-813.
10. Abumrad NA, el-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA, (1993) Cloning of a rat adipocyte membrane protein implicated in binding or transport of long chain fatty acids that is induced during preadipocyte differentiation, Homology with human CD36. J Biol Chem 268: 17665-17668.
11. Baillie AG, Coburn CT, Abumrad NA, (1996) Reversible binding of long chain fatty acid to purified FAT, the adipose CD36 homolog. J Memb Biol 153: 75-81.
12. Ibrahimi A, SfeirZ, Magharaie H, Amri EZ, Grimaldi P, et al. (1996) Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. Proc Natl Acad SCI USA 9: 2646-2651.
13. Nauli AM, Nassir F, Zheng S, Yang Q, Lo CM, et al. (2006) CD36 is important for chylomicron formation and secretion and may mediate cholesterol uptake in the proximal intestine. Gastroenterology 131: 1197-1207.
14. Nassir F, Wison B, Han X, Gross RW, Abumrad NA, (2007) CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. J. Biol. Chem. 282: 19493-19501.
15. Drover VA, Nguyen DV, Bastie CC, Darlington YF, Abumrad NA, et al. (2008) CD36 mediates both cellular uptake of very long chain fatty acids and their intestinal absorption in mice. J Biol Chem 283: 13108-13115.
16. Yang J, Sambandam N, Han X, Gross RW, Courtois M, et al. (2007) CD36 deficiency rescues lipotoxic cardiomyopathy. Circulation Research 100: 1208-1217.
17. Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, et al. (2007) Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 56: 2863-2871.
18. Tran TTT, Poirier H, Clement L, Nassir F, Pelsers MMAL, et al. (2011) Luminal lipid regulates CD36 levels and downstream signaling to stimulate chylomicron synthesis. J Biol Chem 286: 25201-25211.
19. Masuda D, Hirano K, Oku H, Sandoval JC, Kawase R, et al. (2009) Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J Lipid Res 50: 999-1011.
20. Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, et al. (1999) Muscle-specific over expression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, and increases plasma glucose and insulin. J Biol Chem 274: 27761-26766.
21. Griffin E, Re A, Hamel N, Fu C, Bush H, et al. (2001) A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nature Med 7: 840-846.
22. Furuhashi M, Ura N, Nakata T, Shimamoto K, (2003) Insulin sensitivity and lipid metabolism in human CD36 deficiency. Diabetes Care 26: 471-474.
23. Goudriaan JR, Dahlmans VE, Teusink B, Ouwens DM, Febbraio M, et al. (2003) CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res 44: 2270-2277.
24. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, et al. (2004) Increased CD36 protein as a response to defective insuline signalling in macrophages. J Clin Invest 113: 764-773.
25. Sukhanov S, Higashi Y, Shai SY, Itabe H, Ono K, et al. (2006) Novel effect of oxidized low-density lipoprotein. Circ Res 99: 191-200.
26. Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, et al. (2004) Weight-loss-associated induction of peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin resistant mice. Circulation 110: 3259-3269.
27. Abumrad NA, el Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA, (1993) Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem 268: 17665-17668.
28. Teboul L, Febbraio M, Gaillard D, Amri EZ, Silverstein R, et al. (2001) Structural and functional characterization of the mouse fatty acid translocase promoter: activation during adipose differentiation. Biochem J 360: 305-12.
29. Febbraio M, Hajjar DP, Sylverstein RL, (2001) CD36 A class B scavenger receptor involved in Angigenesis, atherosclerosis, and lipid metabolism. J Clin Invest 108: 785-791.
30. Dawson DW, Pearce SFA, Zhong R, Siverstein RL, Frazier WA, et al. (1997) CD36 mediates the inhibitory effects of thrombospondin-I on endothelial cells. J Cell Biol 138: 707-717.
31. Tontonoz P, Naggy L, Alvarez JG, Thomazy VA, Evans M, (1998) PPARγ promotes monocytes/macrophage differentiation and uptake of ox-LDL. Cell 93: 241-252.
32. Savill J, Hogg N, (1992) Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 90: 1513-1522.
33. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, et al. (1998) Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and crosspresent antigens to cytotoxic T lymphocytes. J Exp Med 188: 1359-1368.
34. Ring A, Le Lay S, Pohl J, Verkade P, Stremmel W, (2006) Caveolin-1 is required for fatty acid translocase (FAT/CD36) localization and function at the plasma membrane of mouse embryonic fibroblasts. Biochim Biophys Acta 1761: 416-423.
35. Lynes MD, Widmaier EP, (2011) Involvement of CD36 and intestinal alkaline phosphatases in fatty acid transport in enterocytes, and the response to a high-fat diet. Life Sci 88: 384-391.
36. Huang W, Febbraio M, Sylverstein RL, (2011) CD9 tetraspin interacts with CD36 on the surface of Macrophages: A possible regulatory influence on uptake of ox-LDL. PloS ONE 6: e29092.
37. Miao WM, Vasile E, Lane WS, Lawler J, (2001) CD36 associates with CD9 and integrins on human blood platelets. Blood 97: 1689-1696.
38. Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, et al. (2006) Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem 281: 31002-31011.
39. Goudrian JR, den Boer MAM, Rensen CN, Febbraio M, Kuipers F, et al. (2005) CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. Journal of Lipid Research 46: 2175-2181.
40. Love-Gregory L, Sherva R, Sun L, Wasson J, Schappe T, et al. (2008) Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. Human Molecular Genetics 17: 1695-1704.
41. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, et al. (1996) Insulin sensitivity and atherosclerosis, the insulin resistance atherosclerosis study (IRAS) investigators. Circulation 93: 1809-1817.
42. Howard BV, Magee MF, (2000) Diabetes and cardiovascular disease. Curr Atheroscler Rep 2: 476-481.
43. Haffner SM, (2002) Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol 90: 55i-61i.
44. Plutzky J, Viberti G, Haffner S, (2002) Atherosclerosis in type 2 diabetes mellitus and insulin resistance, mechanistic links and therapeutic targets. J Diabetes Complications, 16° pp. 401-415.
45. Lamharzi N, Renard CB, Kramer F, Pennathur S, Heinecke JW, et al. (2004) Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions. Diabetes 53: 3217-3225.
46. Kennedy DJ, Kushibhotla S, Westfall KM, Sylverstein RL, Morton RE, et al. (2011) A CD36-dependent pathway enhances macrophage and adipose tissue inflammation and impairs insulin signaling. Cardiovascular Res 89: 604-613.
47. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, et al. (2004) Increased CD36 protein as a response to defective insulin signalling in macrophages. J Clin Invest 113: 764-773.
48. Masson CJ, Plat J, Mensink MP, Namiot A, Kisielewski W, et al. (2009) Fatty-acid and cholesterol transporter protein expression along the human intestinal tract. PloS ONE 5: e10380.
49. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, et al. (2007) Fasting compared with non-fasting triglycerides and risk of cardiovascular events in women. JAMA 298: 309-31.